BLACK WEEKSVialer −15% · kit −10% · övrigt −5%med kodFri frakt inom Tyskland från €200

Den här sidan har översatts automatiskt och kan innehålla fel. Har du svenska som modersmål? Vi tar gärna emot din feedback och dina förbättringar.Skicka feedback

The Peptide Desk The Peptide Desk

Den här informationen är enbart för forsknings- och utbildningsändamål. Inga medicinska rekommendationer. Produkterna är inte godkända för användning på människor. Vid hälsofrågor, kontakta en läkare.

Lexikon

Pregabalin (Lyrica)

The gabapentinoid with predictable kinetics: over 90 percent bioavailability regardless of dose, no hepatic involvement, but a documented abuse potential.

8 min read 7 sources

Small blue 3D molecule with white and one light blue atom above a white podium in a bright lab
Compound approved · since 2004

Summary

At a glance

Sources checked on 26 Oct 2026

Bioavailability
≥90 %

Independent of the amount, gabapentin by contrast falls as the amount rises1

Half-life
~6 hours

Excreted unchanged via the kidney, no liver metabolism1

Per one additional benefit
3.9 people

Nerve pain after shingles, middle level, at least 30 percent less pain2

Effect size in anxiety disorder
0.37 Hedges g

8 trials, 2,299 participants, small to medium3

Misuse in the population
1.6 %

Gabapentinoids overall, among opioid users 3 to 68 percent4

  • Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels. Less calcium flows in and fewer excitatory messengers are released.17
  • It is absorbed fast, linearly and to at least 90 percent, not metabolised in the liver and excreted unchanged via the kidney.1
  • In nerve pain after shingles clearly more participants reached noticeable pain relief than on placebo, in diabetic neuropathy the effect was small, in HIV neuropathy it was absent.2
  • Dizziness and sleepiness rose with the level. A review documents misuse, especially in people with a history of opioid use.24
  • Everything here is the state of research, not a recommendation.7
Profil

Updated October 2026

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~6 hours

Half-life ~6 hours
After 12 hours: 25 %
Hour 6 · 50 %Hour 12 · 25 %Hour 18 · 12.5 %Hour 30 · 3.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Class
Gabapentinoid, alpha-2-delta ligand

does not act at the GABA receptor

Use
Oral tablet

split into 2 to 3 doses per day from 150mg upwards

Half-life
about 6 hours
Bioavailability
over 90 percent

independent of dose

Elimination
almost entirely unchanged via the kidney

no hepatic metabolism

Status
Clinically approved

neuropathic pain, adjunct in epilepsy, GAD in the EU, controlled substance in the UK and US

Sizes
150 to 300 mg

3 sizes in the shop

Innehåll 13 sections
  1. I korthet
  2. What is pregabalin?
  3. How it works
  4. Pharmacokinetics: the difference from gabapentin
  5. Use and dosing
  6. What the research shows
  7. Forskningsläge
  8. Side effects
  9. Storage
  10. Relaterade substanser
  11. Vanliga frågor
  12. Ordlista
  13. Källor

What is pregabalin?

Pregabalin (brand name Lyrica) is a gabapentinoid, a compound from the same family as gabapentin. Chemically it is a derivative of the amino acid GABA. That name misleads people all the time: pregabalin does not bind GABA receptors and does not behave like a GABA agent in any other way either. It was developed as the successor to gabapentin with one clear goal, getting rid of gabapentin's unpredictable absorption.

Clinically, pregabalin is approved in the EU for neuropathic pain, as add-on for focal seizures and for generalized anxiety disorder. In the US it is additionally approved for fibromyalgia. Its defining feature, though, is not the breadth of indications but the pharmacokinetics: linear, fast and liver-free. In a research context that is why pregabalin often serves as the reference gabapentinoid.

This entry covers pregabalin as a tablet with 50, 300 or 450mg of active ingredient, in blisters of 10 (50 and 300mg) or 15 tablets (300 and 450mg).

This information is for research and educational purposes only. No medical advice.

Comparison

Drugs for nerves, sleep and muscles

Compounds in the TPD lexicon and their target according to ChEMBL. Tap a card to open its entry.

Alpha-2-delta ligand Pregabalin (Lyrica) α2δ
GABA-A modulator Zopiclone (Imovane) GABA-A Serotonin antagonist Trazodone (Trittico) 5-HT2A
Muscle relaxant, tricyclic Cyclobenzaprine ER (Amrix) 5-HT2A

Simplified: pregabalin does not act at the GABA receptor like zopiclone but at a subunit of calcium channels. 71

How it works

Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels located at nerve terminals. That subunit helps govern how many channels sit in the membrane and how much calcium enters during an action potential. Less calcium influx means less release of excitatory messengers such as glutamate, noradrenaline and substance P. Pregabalin and gabapentin share this mechanism (Bockbrader et al. 2010).

The effect is largest where neurons fire in an overexcited state: in sensitized pain pathways, in an epileptic focus or in anxiety circuits. In a quiet system little happens. That also explains why the effect on pain or anxiety is not there after an hour, even though plasma levels already are, but builds over days.

What pregabalin does not do: it does not bind GABA-A or GABA-B, does not alter GABA uptake and is not a sodium channel blocker. The sedation many people experience comes from dampened excitatory transmission, not from a benzodiazepine-like mechanism.

Where it acts

Where pregabalin acts

Tap a point or a card. Colour = alpha-2-delta binding, grey = observed in studies.

  1. Brain and nerves

    Less calcium influx, fewer excitatory messengers, effect in nerve pain, seizures and anxiety1

    α2δ
  2. Kidney

    Excreted unchanged via the kidney, clearance falls with kidney function5

    Observed in trials
  3. Liver

    No metabolism in the liver, no inhibition of liver enzymes1

    Observed in trials

Targets in the ChEMBL database7

Compound CHEMBL1059: one recorded mechanism, Modulator.

Alpha-2-delta subunit of voltage-gated calcium channels
Gene
CACNA2D1, CACNA2D2
UniProt
P54289, Q9NY47
ChEMBL
CHEMBL2363032
Action
Modulator
Glass nerve ending with blue molecules and vesicles, below it few messenger droplets above glass docking sites
Less calcium, fewer excitatory messengers at the nerve ending. Symbolic image.

Pharmacokinetics: the difference from gabapentin

Bockbrader and colleagues (Clinical Pharmacokinetics 2010) put the two gabapentinoids side by side. Gabapentin is absorbed through a saturable transporter, its absolute bioavailability falls from 60 to 33 percent as the daily dose rises from 900 to 3600mg. Peak concentration arrives only after 3 to 4 hours. Pregabalin reaches its plasma peak within about an hour and absorption is linear. Bioavailability stays at 90 percent or more no matter the dose. Double the dose, double the level.

  • Plasma proteins: no binding.
  • Liver: no metabolism, no inhibition or induction of CYP enzymes. Interactions via the hepatic route practically do not exist.
  • Food: can be taken with or without a meal, total absorption does not change.
  • Elimination: renal, unchanged, elimination half-life around 6 hours. Levels are therefore stable after one to two days of steady dosing.

The flip side of pure renal elimination was measured by Randinitis and colleagues (Journal of Clinical Pharmacology 2003) in 38 people across the range of kidney function plus 12 dialysis patients: total and renal clearance fall in proportion to creatinine clearance. Area under the curve and half-life rise accordingly. Hemodialysis removes a large share of the drug. If you do not know your kidney function, you do not know your actual exposure.

Use and dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts
White folding box with the TPD logo next to a blister with ten white tablets, two loose tablets in front
Pregabalin as a tablet in a blister. Symbolic image.

What the research shows

The densest evidence is in neuropathic pain. Derry and colleagues (Cochrane 2019) analysed 45 randomized, double-blind trials with 11,906 participants at 150, 300 and 600mg per day. In postherpetic neuralgia, 50 percent on 300mg achieved at least a 30 percent pain reduction versus 25 percent on placebo; on 600mg it was 62 versus 24 percent. At 300mg, roughly four participants corresponded to one additional person with a noticeable benefit (NNT 3.9). In painful diabetic neuropathy the effect was far smaller (47 versus 42 percent on 300mg). In HIV neuropathy there was no benefit. The authors' summary: some derive substantial benefit, more derive moderate benefit and many get nothing or discontinue. Serious adverse events were no more frequent than on placebo in the trials.

In generalized anxiety disorder, Generoso and colleagues (International Clinical Psychopharmacology 2017) pooled eight randomized trials with 2,299 participants. Pregabalin beat placebo with a Hedges g of 0.37, a small to moderate effect size, with no sign of publication bias and no meaningful heterogeneity between trials. Dropout rates did not differ from placebo. In clinical response pregabalin sat roughly level with benzodiazepines, with fewer dropouts.

Bockbrader and colleagues (2010) rank the analgesic potency such that 450mg pregabalin per day corresponds roughly to the predicted maximum effect of gabapentin. They see a possible edge for pregabalin as an antiepileptic. Honest summary: the kinetics are what set pregabalin apart from gabapentin. The effect sizes are solidly documented but moderate. They depend heavily on whether someone belongs to the responders.

Study results

What the trials measured

Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.

Noticeably less pain2

Nerve pain after shingles, share with at least 30 or 50 percent less pain

At least 30%, middle level2
Placebo 25%
Middle level 50%
At least 30%, highest level2
Placebo 24%
Highest level (highest study dose, 600 mg per day) 62%
At least 50%, middle level2
Placebo 13%
Middle level 32%
At least 50%, highest level2
Placebo 15%
Highest level (highest study dose, 600 mg per day) 41%

Cochrane review, 3 to 4 trials with 537 to 732 participants each, trials 2 to 16 weeks. Placebo values per comparison.

Noticeably less pain2

Painful diabetic neuropathy, share with at least 30 or 50 percent less pain

At least 30%, middle level2
Placebo 42%
Middle level 47%
At least 30%, highest level2
Placebo 52%
Highest level (highest study dose, 600 mg per day) 63%
At least 50%, middle level2
Placebo 24%
Middle level 31%
At least 50%, highest level2
Placebo 28%
Highest level (highest study dose, 600 mg per day) 41%

Placebo was already high here and the advantage was small: one additional benefit at the middle level took about 22 participants. In HIV neuropathy no benefit showed.

Cross-section of a glass nerve with bundled light blue fibres on a bright surface
Studies on nerve pain, anxiety disorder and misuse. Symbolic image.

Research status

Where the research stands

Selection from 636 entries on ClinicalTrials.gov. Most test pain after surgery or nerve pain, plus fibromyalgia, epilepsy and anxiety disorder. As of 26 Oct 2026. 6

  1. Preclinical Same mode of action as gabapentin, more predictable absorption
  2. Phase 1 no registered trial
  3. Phase 2 no registered trial
  4. Phase 3 10 trials, 8 completed, 2 stopped early
  5. Approval since 2004
3,276 participants in phase 3 Approved: ChEMBL lists pregabalin with phase 4 and first approval in 2004.7
Show all 10 phase 3 trials on a timelineHide timeline 8 completed 0 running 2 stopped early 0 with results
Phase 3

Bar: start to primary endpoint (planned for running trials). Green = completed, blue = progress until 26 Oct 2026, grey = stopped early.

Side effects

  • Dizziness and somnolence: the two most common reports, clearly dose-dependent. In the Cochrane review for postherpetic neuralgia, 29 percent dizziness and 16 percent somnolence on 300mg, 35 and 25 percent on 600mg, versus 8 and 6 percent on placebo. Strongest in the first days and after every increase. Reaction time and fitness to drive are directly affected.
  • Weight gain and fluid retention: regularly reported in the registration data, rising with dose. Swollen ankles are not a reason for diuretics but a hint about the dose.
  • Blurred vision, dry mouth, trouble concentrating: common, mostly mild and receding.
  • Abuse and dependence: Evoy and colleagues (Drugs 2017) reviewed 59 studies. In the general population the prevalence of gabapentinoid abuse was 1.6 percent, among opioid users between 3 and 68 percent. An international database counted 11,940 reports between 2004 and 2015, more than three quarters of them from 2012 onwards. Risk factors are psychiatric comorbidity and a substance history, especially with opioids. Pregabalin is increasingly found in post-mortem toxicology.
  • Combination with opioids, benzodiazepines and alcohol: the depressant effects add up, as far as respiratory depression. That is the route by which gabapentinoids feature in fatalities. Drug regulators have warned explicitly about it since 2019.
  • Withdrawal: after an abrupt stop, insomnia, nausea, headache, restlessness, sweating and diarrhea are described. Taper over at least one week.
  • Mood: as for all antiepileptics there is a class warning about suicidal thoughts. New or worsening low mood is a reason to reconsider use.
  • Kidney function: because elimination is almost entirely renal, exposure multiplies with impaired kidneys unless the dose is adjusted. See dosing.
  • Pregnancy and breastfeeding: per the prescribing information only to be used if clearly necessary. Pregabalin passes into breast milk. Malformation data are sparse and contradictory. A small additional risk cannot be ruled out.
  • Legal status: classified as a controlled substance in the UK since 2019 and in the US, prescription-only in Germany. Check the situation where you live.

Rare but documented: angioedema and hypersensitivity reactions, with a higher risk in combination with ACE inhibitors. Swelling of the face, mouth or throat is a reason to stop immediately and seek medical assessment.

Tolerability

Dizziness and sleepiness

Out of 100 participants, in how many dizziness or sleepiness occurred.

8 of 100 Placebo
29 of 100 Middle level
Event PlaceboMiddle level
Dizziness, middle level2 8%29%
Dizziness, highest level2 9%0%
Sleepiness, middle level2 6%16%
Sleepiness, highest level2 6%0%

Serious side effects were not more common than on placebo across all pain types (about 3 percent). In anxiety disorder no more participants dropped out than on placebo.23

Storage

Store dry, at room temperature and protected from light. Leave tablets in the blister until you need them and keep them out of reach of children. Pregabalin is chemically stable, but use split tablets promptly rather than leaving halves around for weeks.

Three white tablet bottles and a folded light blue towel on a white shelf
Store dry, at room temperature and protected from light in the blister. Symbolic image.

Related

Related compounds

A different path: all in the TPD lexicon.

FAQ

Common questions about Pregabalin (Lyrica)

Short answers, each backed by the sources below.

How does pregabalin work?

Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels at nerve endings. Less calcium flows in and fewer excitatory messengers are released. Gabapentin shares this mode of action.17

How does pregabalin differ from gabapentin?

Mainly the absorption. Pregabalin reaches its peak level after about one hour, gabapentin after 3 to 4 hours. Pregabalin is absorbed linearly and bioavailability stays at 90 percent or more. With gabapentin it falls from 60 to 33 percent as the amount rises. Neither binds to blood proteins, neither is metabolised in the liver and both are excreted via the kidney.1

How well does it work for nerve pain?

The Cochrane review with 45 trials and 11,906 participants shows: in nerve pain after shingles 50 percent reached at least 30 percent less pain at the middle level, on placebo 25 percent. In diabetic neuropathy the advantage was small, in HIV neuropathy there was none. According to the authors some benefit clearly, more moderately and many not at all.2

And in generalised anxiety disorder?

A meta-analysis of 8 trials with 2,299 participants found pregabalin better than placebo with a small to medium effect size (Hedges g 0.37) and no sign of publication bias. Drop-outs were not more common than on placebo. Its effect was about that of benzodiazepines, with fewer drop-outs.3

Why does kidney function matter so much?

Pregabalin leaves the body almost only via the kidney. In 38 people with different kidney function and 12 dialysis patients clearance fell in line with creatinine clearance while levels and half-life rose. Dialysis removes a lot of the drug. The authors recommend reducing the daily amount when the kidney is impaired.5

How high is the risk of misuse?

A review of 59 studies found misuse of gabapentinoids in 1.6 percent of the population and in 3 to 68 percent of opioid users. An international database counted 11,940 reports between 2004 and 2015, more than three quarters since 2012. Risk factors are a history of addiction (especially to opioids) and psychiatric conditions. Pregabalin is increasingly found in post-mortem analyses.4

Which side effects are most common?

Dizziness and sleepiness, depending on the level. In nerve pain after shingles 35 percent had dizziness and 25 percent sleepiness at the highest level, on placebo about 9 and 6 percent. Serious side effects were not more common than on placebo.2

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

Alpha-2-delta subunit
Auxiliary part of voltage-gated calcium channels that helps control how many channels sit in the nerve membrane.
Angioedema
Sudden swelling of skin and mucous membranes, for example on the face, mouth or throat.
Bioavailability
Share of a swallowed drug that reaches the blood unchanged.
Creatinine clearance
Measure of how well the kidneys filter the blood.
Gabapentinoid
Drug group of pregabalin and gabapentin, both bind the alpha-2-delta subunit.
Hedges g
Measure of the size of an effect. Around 0.2 counts as small, around 0.5 as medium.
NNT
Number needed to treat: how many participants it takes for one more person to benefit than on placebo.
Placebo
Dummy preparation without active substance. Comparing against it shows what is due to the substance itself.
Postherpetic neuralgia
Nerve pain that remains after shingles.
Respiratory depression
Dangerously shallow and slow breathing, for example when several sedating drugs come together.

Evidens

Källor

Show all 7 sourcesHide sources 5 Studies1 Trial registry1 Database checked 26 Oct 2026

Studies

  1. Pregabalin and gabapentin compared: kinetics and effect

    Bockbrader et al., Clinical Pharmacokinetics, 2010

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Cochrane review: pregabalin in nerve pain, 45 trials

    Derry et al., Cochrane Database of Systematic Reviews, 2019

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. Meta-analysis: pregabalin in generalised anxiety disorder

    Generoso et al., International Clinical Psychopharmacology, 2017

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  4. Review of misuse of pregabalin and gabapentin

    Evoy et al., Drugs, 2017

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  5. Kinetics with different kidney function and dialysis

    Randinitis et al., Journal of Clinical Pharmacology, 2003

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Pregabalin trials on ClinicalTrials.gov

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. Pregabalin in ChEMBL (target and approval)

    ChEMBL, EMBL-EBI (CHEMBL1059)

    Checked 26 Oct 2026 via ChEMBL

I butiken

Pregabalin (Lyrica) in the catalog

Storlekar, priser och leveranstider finns på produktsidan.

Till produkten